Navigation Links
Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
Date:11/15/2010

39.3% compared to $2.9 million for the same period in 2009. This increase was primarily due to a relative increase in bad debt expense. Selling, general and administrative expenses as a percentage of sales were 39.1% for the third quarter of 2010 compared to 30.9% for the same period in 2009. For the nine months ended September 30, 2010, selling, general and administrative expenses were $11.6 million, an increase of 15.6% compared to $10.1 million in the same period in 2009. This increase was mainly due to the aforementioned increase in bad debt expense. For the nine months ended September 30, 2010, selling, general and administrative expenses as a percentage of sales were 38.8%, compared to 20.9% for the same period in 2009.

As of September 30, 2010, Tiens had $128.5 million of retained earnings and total shareholders' equity of $195.3 million.

Jinyuan Li, Chairman, President and CEO of Tiens, said, "We are pleased to report an increase in domestic sales which we believe will continue in the future. Our total revenue decline should be temporary since both our domestic and global affiliated companies have not witnessed significant declines in their overall revenue. We are committed to expanding our international customer base and generating long-term domestic and international growth."

About Tiens Biotech Group (USA), Inc. www.tiens-bio.com

Tiens Biotech Group (USA), Inc. (NYSE AMEX: TBV) conducts its business operations from Tianjin, People's Republic of China. Tiens primarily engages in the research, development, manufacturing, and marketing of nutrition supplement products, including wellness products and dietary supplements.

Tiens derives its revenues principally from product sales to affiliated companies in China and internationally in 54 countries.  Since its establishment, Tiens has developed an
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
4. Tiens Biotech Group (USA) Reports First Quarter Results
5. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. Yongye Biotechnology International Retains CCG Investor Relations
8. ThirdBiotech Announces Kemeta as Newest Sponsor
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
11. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... N.J. , March 3, 2015  Regenicin, Inc. ... company specializing in the development of and commercialization of ... tissues and organs, announced today that it has received ... with Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... the Agreement, Amarantus made the final payments due to ...
(Date:3/3/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... Expert Opinion on Biological Therapy , Dr. ... Zhang , at the Henry Ford Hospital in ... 4 (TB4) has the capacity to promote CNS and ... post-injury, leading to neurological recovery in each case.  They ...
(Date:3/3/2015)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a ... pets, announced today that it will release its fourth quarter ... the market close. The Company will host a conference call ... Interested parties may access the call by dialing toll-free (855) ... conference ID 98449349.  The call will also ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Personalized Medicine - ... , The aim of personalized ... right drug to the right patient and, in ... for a patient according to his/her genotype. This ...
Breaking Biology Technology:Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3
... Jan. 27 Alfacell Corporation (OTC Bulletin Board: ACEL) ... with the U.S. Food and Drug Administration (FDA) to ... of the ONCONASE rolling New Drug Application (NDA) for ... At the pre-NDA meeting, the FDA provided guidance to ...
... RELY ON INFORMATION PUBLISHED BY UNIVERSAL , NETTLETON, ... Sheets: UBRG) announces that certain unauthorized inaccurate information ... report on BeaconEquity.com website, potentially other websites and ... these materials, the company has found errors in ...
... Webcast Scheduled for Tuesday, February 3, 2009 SAN DIEGO, ... NBIX ) announced today that the Company will report ... the Nasdaq market closes on Tuesday, February 3, 2009. ... webcast to discuss its financial results and provide a ...
Cached Biology Technology:Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results 2
(Date:2/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ) ... 2D Gesture Recognition Market 2015-2019" report to ... the Global 2D Gesture Recognition market to grow ... 2014-2019 The increased demand for gesture-enabled ... the major trends in the market. The growing ...
(Date:2/12/2015)... 2015   MedNet Solutions , a global ... management systems, has recently bolstered its ... iMedNet as the eClinical solution ... healthcare consultants.  Building on the Program,s existing benefits ... numerous co-marketing opportunities), MedNet,s new and improved program ...
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... with intelligence as a beneficial trait, according to ... Medical Center and other institutions. Jeremy Coplan, MD, ... found that high intelligence and worry both correlate ... the nutrient choline in theGlaxoSmithKline Pharmaceuticals, Sackler Institute ...
... Scientists at the Allen Institute for Brain Science have identified ... the brains of human individuals, and between humans and mice ... brain. The study, published online today in the journal ... and also serves as an introduction to what the associated ...
... - - Finger Vein Identity Management ... - - Hitachi Europe Ltd. and M2SYS ... partnership making M2SYS Hitachi,s primary Value Added Reseller in North ... Biometric Finger Vein identity management scanning technology was developed by ...
Cached Biology News:Excessive worrying may have co-evolved with intelligence 2Fine-scale analysis of the human brain yields insight into its distinctive composition 2Fine-scale analysis of the human brain yields insight into its distinctive composition 3M2SYS Technology Partners with Hitachi to Offer Innovative Biometric Finger Vein Scanner to US Market 2
Auto/Zyme Reagent...
4',6-Diamidino-2-phenylindole dihydrochloride...
...
Normal Bovine Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin lev...
Biology Products: